4Tontini M, Berti F, Romano MR, et al. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines. Vaccine, 2013, 31 (42):4827- 4833.
5WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. Geneva: World Health Organization, 2009 [2016-01-29]. http://www.who.int/biologieals/ areas/vaccines/pneurno/Pneumo final 23APRIL_2010.pdf?ua=1.
6Centers for Disease Control and Prevention (CDC), Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep, 2011, 60(1):13-15.
7Aggerbeck H, Heron I. Detoxification of diphtheria and tetanus toxin with formaldehyde. Detection of protein conjugates. Biologicals, 1992, 20(2):109-115.
8Relyveld EH, Henocq E, Bizzini B. Studies on untoward reactions to diphtheria and tetanus toxoids. Dev Biol Stand, 1979, 43:33-37.
9Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenza protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatric Infect Dis J, 2009, 28(4 Suppl):S66-S76.
10Gross S, Janssen SW, de Vries B, et al. Collaborative study for the validation of alternative in vitro potency assays for human tetanus imrnunoglobulins. Biologicals, 2010, 38(4):501-510.
